NCT04017702 is a clinical trial of Expiron respirator in Respiratory Depression, sponsored by Yale University.

Who is sponsoring NCT04017702?

NCT04017702 is sponsored by Yale University.

What drugs are being tested in NCT04017702?

Interventions in NCT04017702: Expiron respirator.

What condition does NCT04017702 study?

NCT04017702 studies Respiratory Depression.

Is NCT04017702 still recruiting?

NCT04017702 is currently completed. Last updated 1 April 2022.

Last reviewed 2022-04-01 · How we verify

NCT04017702

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Detection of Postoperative Respiratory Depression in High Risk Patients Utilizing Minute Ventilation Monitoring

Completed Last updated 1 April 2022

What this trial tests

trial testing Expiron respirator in Respiratory Depression in 86 participants. Completed in 20 February 2020.

Timeline

20 June 2018

Primary endpoint
20 February 2020

20 February 2020

Quick facts

Lead sponsor	Yale University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	86
Start date	20 June 2018
Primary completion	20 February 2020
Estimated completion	20 February 2020
Sites	1 location across United States

Drugs / interventions tested

Expiron respirator

Conditions studied

Respiratory Depression — all drugs for Respiratory Depression →

Sponsor

Yale University

Who can join

Adults 18 to 80, any sex, with Respiratory Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Respiratory volume monitor (RVM) (ExSpiron) is superior to continuous pulse oximetry in detection of postoperative respiratory depression in high risk patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Respiratory Depression

Currently open trials in the same condition.

NCT07166614 — Dexmedetomidine vs Propofol in High-Risk ERCP Patients · NA · recruiting
NCT06967259 — ENA-001 for Opioid Induced Respiratory Depression · Phase 1 · active not recruiting
NCT06823661 — Transcutaneous Electrical Stimulation for Apnea Detected by Capnography · NA · recruiting
NCT06777758 — Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments · Phase 4 · recruiting
NCT06772961 — Effect of Percutaneous Electrical Acupoint Stimulation on the Improvement of Incidence of Adverse Respiratory Events · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04017702 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 1 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04017702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing